Zenas BioPharma Statistics

Total Valuation

Zenas BioPharma has a market cap or net worth of $1.07 billion. The enterprise value is $730.06 million.

Market Cap	1.07B
Enterprise Value	730.06M

Important Dates

The last earnings date was Monday, March 16, 2026, before market open.

Earnings Date	Mar 16, 2026
Ex-Dividend Date	n/a

Share Statistics

Zenas BioPharma has 59.49 million shares outstanding. The number of shares has increased by 238.89% in one year.

Current Share Class	59.49M
Shares Outstanding	59.49M
Shares Change (YoY)	+238.89%
Shares Change (QoQ)	+25.71%
Owned by Insiders (%)	1.62%
Owned by Institutions (%)	59.32%
Float	36.53M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	107.19
Forward PS	n/a
PB Ratio	4.05
P/TBV Ratio	4.43
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	73.01
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.61, with a Debt / Equity ratio of 0.01.

Current Ratio	5.61
Quick Ratio	5.50
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-28.85

Financial Efficiency

Return on equity (ROE) is -136.22% and return on invested capital (ROIC) is -47.44%.

Return on Equity (ROE)	-136.22%
Return on Assets (ROA)	-35.06%
Return on Invested Capital (ROIC)	-47.44%
Return on Capital Employed (ROCE)	-65.85%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	$59,880
Profits Per Employee	-$2.26M
Employee Count	167
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

Income Tax	-79,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +79.74% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+79.74%
50-Day Moving Average	22.77
200-Day Moving Average	24.12
Relative Strength Index (RSI)	34.54
Average Volume (20 Days)	737,740

Short Selling Information

The latest short interest is 10.22 million, so 17.19% of the outstanding shares have been sold short.

Short Interest	10.22M
Short Previous Month	9.36M
Short % of Shares Out	17.19%
Short % of Float	27.99%
Short Ratio (days to cover)	9.96

Income Statement

In the last 12 months, Zenas BioPharma had revenue of $10.00 million and -$377.74 million in losses. Loss per share was -$8.44.

Revenue	10.00M
Gross Profit	10.00M
Operating Income	-211.39M
Pretax Income	-377.82M
Net Income	-377.74M
EBITDA	-211.33M
EBIT	-211.39M
Loss Per Share	-$8.44

Full Income Statement

Balance Sheet

The company has $343.19 million in cash and $1.33 million in debt, giving a net cash position of $341.87 million or $5.75 per share.

Cash & Cash Equivalents	343.19M
Total Debt	1.33M
Net Cash	341.87M
Net Cash Per Share	$5.75
Equity (Book Value)	242.14M
Book Value Per Share	4.44
Working Capital	288.52M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$172.33 million and capital expenditures -$18,000, giving a free cash flow of -$172.35 million.

Operating Cash Flow	-172.33M
Capital Expenditures	-18,000
Depreciation & Amortization	56,000
Net Borrowing	n/a
Free Cash Flow	-172.35M
FCF Per Share	-$2.90

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-2,113.85%
Pretax Margin	-3,778.16%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Zenas BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-238.89%
Shareholder Yield	-238.89%
Earnings Yield	-35.24%
FCF Yield	-16.08%

Analyst Forecast

The average price target for Zenas BioPharma is $42.14, which is 133.98% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$42.14
Price Target Difference	133.98%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	81.00%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zenas BioPharma has an Altman Z-Score of -0.33 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.33
Piotroski F-Score	2